• Publications
  • Influence
Initial Poor Function and Primary Nonfunction in Deceased-Donor Orthotopic Liver Transplantation Maintaining Short Cold Ischemic Time
Background: Nations with emerging deceased-donor liver transplantation programs, such as India, face problems associated with poor donor maintenance. Cold ischemic time (CIT) is typically maintainedExpand
  • 4
THU0198 Immunogenicity associated with a transition from adalimumab reference product to abp 501 in patients with rheumatoid arthritis
Background In clinical practice, patients treated with an originator product may be transitioned to a biosimilar. Therefore, it is important to ensure that such transition is safe and is notExpand
  • 1
SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis
Background: Biosimilars are expected to have similar long-term safety profiles as originator products. Objectives: To describe the consolidated, 2-year safety data on ABP 501, an approved biosimilarExpand
AB0380 Results from a randomized, single-blind, single-dose, parallel-group study in healthy subjects demonstrating pharmacokinetic similarity between abp 710 and infliximab
Background ABP 710 is being developed as a biosimilar with the same amino acid sequence as infliximab, an anti-tumor necrosis factor therapy. Analytical and functional comparisons between ABP 710 andExpand
FRI0115 Indirect standardised assessment of injection site pain following subcutaneous administration of citrate-free formulation of adalimumab and its biosimilar abp 501
Background In randomised double-blind studies in patients with rheumatoid arthritis (RA) and psoriasis (PsO), ABP 501, an approved adalimumab biosimilar, had significantly lower injection site painExpand
Multidetector Computed Tomographic Characterization of a Rare Retroperitoneal Mass in the Left Psoas Compartment
We discuss a case of a rare, large, left-sided retroperitoneal mass that presented a diagnostic difficulty in characterization both radiologically and pathologically. We analyze the imaging findingsExpand
AB0457 Clinical equivalence in efficacy between abp 501 and adalimumab in patients with moderate to severe rheumatoid arthritis: a tipping point sensitivity analysis
Background ABP 501 is the first approved biosimilar to adalimumab. Patient withdrawals from clinical trials can result in missing data, which may lead to loss of statistical power and bias of theExpand